Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

BMS-986458 a Potential First-in-Class, Highly Selective, Potent and Well Tolerated BCL6 Ligand Directed Degrader (LDD) Demonstrates Multi-Modal Anti-Tumor Efficacy for the Treatment of B-Cell Non-Hodgkin's Lymphoma

Blood (2024) 144 (Supplement 1): 957.

https://doi.org/10.1182/blood-2024-210951

Published: 2024

Journal Articles

Multi-Omics Integration to Elucidate the Cis-Regulatory Network Re-Wiring upon NSD2 Degradation in t(4;14) Multiple Myeloma

Bo Hu, Hardik Modi, Diana Jankeel, Jacob T. Edwards, Junfei Zhao, Chad C. Bjorklund, Gaurav Jain, Patrick R. Hagner, Maria Ortiz, Zhongying Mo, Celia Fontanillo, Christoph W. Zapf, Antonia Lopez-Girona, Neil Bence, Kai Wang, Anita K. Gandhi, Mark Rolfe, Deborah S. Mortensen, Lynda Groocock

Blood (2024) 144 (Supplement 1): 1881.

https://doi.org/10.1182/blood-2024-203621

Published: 2024

Journal Articles

Elucidating the Molecular Mechanisms of Action of CC-99282, a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent, Via Genome-Wide CRISPR Screen in a Preclinical Model of Non-Hodgkin Lymphoma (NHL)

Zhongying Mo, Lynda Groocock, Scott Wood, Diana Jankeel, Preethi Janardhanan, Derek Mendy, Michael Angelo, In Sock Jang, Celia Fontanillo, Kai Wang, Mark Rolfe, Antonia Lopez-Girona

Blood (2022) 140 (Supplement 1): 8860–8861.

https://doi.org/10.1182/blood-2022-159393

Published: 2022

Journal Articles

CC-99282 is a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent with Enhanced Tumoricidal Activity in Preclinical Models of Lymphoma

Soraya Carrancio, Lynda Groocock, Preethi Janardhanan, Diana Jankeel, Ryan Galasso, Carla Guarinos, Rama K. Narla, Matthew Groza, Jim Leisten, Daniel W. Pierce, Mark Rolfe, Antonia Lopez-Girona

Blood (2021) 138 (Supplement 1): 1200.

https://doi.org/10.1182/blood-2021-148068

Published: 2021